Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice

Abstract

In the present study, we investigated the effects and mechanisms of action of a combined treatment with etanercept, a soluble tumor necrosis factor receptor (p75) Fc fusion protein, and tacrolimus, a calcineurin inhibitor on the progression of arthritis in human tumor necrosis factor-α (TNF-α) transgenic (hTNF-Tg) mice. Single-drug treatments with etanercept and tacrolimus attenuated the clinical signs but not the radiographic changes associated with the development of arthritis in mice. On the contrary, combined treatment significantly suppressed the radiographic progression and also improved the clinical signs. The combined treatment exhibited synergistic effects of the two drugs in reducing the serum matrix metalloproteinase-3 level and the number of peripheral CD11bhigh osteoclast precursor cells. Moreover, tacrolimus inhibited the cytokine-induced osteoclast differentiation in synergy with etanercept in an in vitro assay. Interestingly, tacrolimus did not inhibit the production of antidrug antibodies (ADAs) against etanercept in the hTNF-Tg mice. This result implies that the synergistic effects of etanercept and tacrolimus are not due to secondary effects derived from the suppression of ADA production by tacrolimus but are due to their primary effects. These findings suggest that concomitant treatment with etanercept and tacrolimus may be one of preferable treatment options to control disease activities for patients with rheumatoid arthritis, especially for those with bone resorption.

Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway

“…Mice in the control group were treated with vehicle cream (Vaseline Lanette cream; Fagron, Waregem, Belgium) in the same way. After 8 days of IMQ (or vehicle cream) administration, mice in the Model+MTX were intraperitoneally injected with methotrexate (MTX, 1 mg/kg/day; Beijing Solarbio Science & Technology Co., Ltd., China) for 12 days, and mice in the Model+Etanercept group were intraperitoneally injected with etanercept (4 mg/kg, once every three days) for 12 days 42,43 . MTX and Etanercept were dissolved in pure water.…”

The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)

“…The potential of combining molecules exerting synergistic or additive effects has first been investigated in experimental arthritis models, paving the way for translating this approach into patients. The combined effect of an anti-TNF (etanercept) and a calcineurin inhibitor (tacrolimus) attenuated arthritis progression in mice, through the suppression of matrix metalloproteinase-3 production and the reduction of osteoclast precursors mobilisation 21. Moreover, acting both on the cellular inhibitors of apoptosis 1 and 2 and the inflammatory cytokine TNFα has proved to reduce the pathological inflammatory milieu long-lastingly, leading to an expansion of regulatory T cells (T reg ) and a reduction of proinflammatory T helper (Th)17 cells 22…”